Home > Boards > US Listed > Medical - Drugs > Sol Gel Technologies Ltd (SLGL)

Aquestive Therapeutics Inc. (AQST)

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 120
Posts 25,365
Boards Moderated 8
Alias Born 02/07/04
160x600 placeholder
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/22/2021 1:25:07 PM
Raymond James: These 3 Stocks Are Poised to Surge by at Least 50% TipRanks - 3/10/2021 10:29:53 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/9/2021 1:07:46 PM
Sol-Gel Technologies reports FY 2020 results Seeking Alpha - 3/4/2021 7:55:57 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/4/2021 7:43:55 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/4/2021 7:38:05 AM
Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update GlobeNewswire Inc. - 3/4/2021 7:05:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/1/2021 6:32:50 AM
Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global ... GlobeNewswire Inc. - 2/24/2021 7:05:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/11/2021 11:13:48 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/5/2021 6:06:42 AM
Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Co... GlobeNewswire Inc. - 1/11/2021 7:05:00 AM
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulga... GlobeNewswire Inc. - 12/7/2020 7:05:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 9:12:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 9:08:36 AM
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update GlobeNewswire Inc. - 11/12/2020 7:05:00 AM
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020 GlobeNewswire Inc. - 11/9/2020 7:05:00 AM
Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020 GlobeNewswire Inc. - 11/4/2020 4:05:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/14/2020 9:14:10 AM
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammat... GlobeNewswire Inc. - 9/10/2020 4:01:10 PM
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September GlobeNewswire Inc. - 9/8/2020 7:05:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/3/2020 8:41:29 AM
Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii® GlobeNewswire Inc. - 9/3/2020 7:05:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 10:40:18 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 10:37:55 AM
midastouch017   Sunday, 04/26/20 09:15:39 AM
Re: DorseyE post# 25
Post # of 36 
Aquestive Therapeutics Inc. (AQST)

Next up is biotech Aquestive Therapeutics, which uses innovative drug delivery technology to redesign important medicines. With not one but two upcoming PDUFA dates, it’s not surprising that members of the Street think its $3.55 share price represents the ideal entry point.
Weighing in for H.C. Wainwright, five-star analyst Raghuram Selvaraju believes that the most valuable piece of the puzzle is its anti-seizure candidate, Libervant, the PDUFA date for which is slated for September 27. “We estimate that Libervant could generate U.S. sales approaching $300 million by 2030. Libervant has been accorded Orphan Drug status, which would confer seven-year market exclusivity upon the product if approved,” he explained.
Regarding Libervant’s launch, Selvaraju argues the fact that Sympazan (clobazam), an oral film for Lennox-Gastaut syndrome (LGS)-associated seizures, was launched prior to Libervant provides Aquestive with the opportunity to set up its commercial infrastructure.
It should also be noted that Selvaraju sees the recent share price weakness as not fully reflecting AQST’s value, with it boasting several other promising candidates in its pipeline. “In our view, the recent coronavirus crisis-driven market disruption has resulted in massively overdone attrition in Aquestive's share price. The company currently trades at a sub-$60 million market cap, which we believe does not reflect even the value of its manufacturing and licensing-related revenue, let alone revenue generated from its proprietary products,” he commented.
One of these candidates is APL-130277, which could be approved on May 21. On top of this, AQST-108 could enter clinical testing this year, and with the annual U.S. epinephrine product market potentially totaling $5.2 billion by 2026, according to Coherent Market Insights, Selvaraju highlights the large opportunity for the biotech.
As a result, Selvaraju reiterated a Buy rating and $13 price target. Should this target be met, a twelve-month gain of 266% could be in the cards. (To watch Selvaraju’s track record, click here)
Looking at the consensus breakdown, other analysts also see big things in store. With 100% Street support, the message is clear: AQST is a Strong Buy. The $17.33 average price target is more aggressive than Selvaraju’s and suggests 388% upside potential. (See Aquestive stock analysis on TipRanks)

https://finance.yahoo.com/news/3-biotech-stocks-under-4-115140896.html

Good luck Dorseye

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences